Table 1 Clinical, ultrasonographic, biochemical parameters of the enrolled women at baseline (m0) and at the 6 (m6) and 12 (m12) months follow up following metformin (1500 mg/d) treatment

Age (years)

28.38 ± 5.53

Weight (Kg)

87.2 ± 18.1

84

82.2 ± 18.1

0.0001

80.05 ± 16.9

0.005

BMI (Kg/m²)

32.8 ± 5.9

32

30.7 ± 5.9

0.0001

30.19 ± 5.7

0.002

Glucose (mg/dL)

91.64 ± 9.66

90

87.90 ± 9.57

0.026

85.91 ± 8.84

0.569

Insulin (μU/mL)

21.03 ± 11.6

18

15.8 ± 8.5

0.001

13.8 ± 7.5

0.02

HOMA-IR

4.83 ± 2.74

4

3.45 ± 1.95

0.0001

2.96 ± 1.71

0.035

Triglycerides (mg/dL)

121.6 ± 61.9

110

121.6 ± 66.4

0.06

112.8 ± 58.5

0.425

Total cholesterol (mg/dL)

189.9 ± 32.5

185

188.6 ± 32.3

0.06

184.1 ± 35.2

0.856

LDL cholesterol (mg/dL)

120.8 ± 26.8

120

115.3 ± 28.2

0.008

118.1 ± 29.0

0.620

HDL cholesterol (mg/dL)

44.1 ± 8.9

43

45.7 ± 9.5

0.003

45.6 ± 9.5

0.674

WHR

0.91 ± 0.1

0,91

0.89 ± 0.09

0.067

0.88 ± 0.09

0.067

T (ng/mL)

0.70 ± 0.31

0,60

0.60 ± 0.29

0.001

0.53 ± 0.24

0.027

SHBG (nmol/L)

23.1 ± 10.4

22

26.4 ± 11.7

0.0001

29.7 ± 13.6

0.002

FAI %

13.2 ± 7.01

9

12.1 ± 6.6

0.0001

11.9 ± 6.04

0.0001

DHEAS (μg/dL)

291.7 ± 125.4

270

278.8 ± 123.2

0.184

272.8 ± 99.8

0.366

4.02 ± 0.65

4

3.89 ± 0.69

0.058

3.85 ± 0.62

0.175

F-G

12.5 ± 6.9

12

12.3 ± 6.5

0.05

11.9 ± 6.04

0.008

LH/FSH

1.44 ± 0.9

1,25

1.19 ± 0.65

0.169

1.09 ± 0.53

0.327

Menses/6 months

2.0 ± 1.7

2

3.5 ± 2.2

0.0001

3.6 ± 2.2

0.024

PCOM (US)

73%

52%

63%

AFC (num- bothovaries)

41 ± 9

40

39 ± 7

0.0001

38 ± 6

0.040